Abstract
Treatment of multi-drug resistant Tuberculosis (MDR-TB) is challenging because it mostly relies on drugs with lower efficacy and greater toxicity than those used for drug-susceptible TB. Aim of the study was to describe the frequency and type of adverse drug reactions in a cohort of MDR-TB patients and their potential impact on treatment outcome. We conducted a retrospective study in a cohort of MDR-TB patients enrolled at a tertiary referral hospital in Italy from January 2008 to December 2016. The records of patients were reviewed for epidemiological, clinical, microbiological and adverse drug reactions data. Seventy-four MDR-TB patients (mean age 32 years, 58.1% males, 2 XDR, 12 pre-XDR TB) were extracted from the Institute data base and included in the retrospective study cohort in the evaluation period (January 2008-December 2016). Median length of treatment duration was 20 months (IQR 14-24). Treatment outcome was successful in 57 patients (77%; 51 cured, 6 treatment completed); one patient died and one failed (2.7% overall); 15 patients were lost to follow-up (20.3%). Sixty-six (89.2%) presented adverse drug reactions during the whole treatment period. Total number of adverse drug reactions registered was 409. Three hund...Continue Reading
References
Feb 28, 2009·The Lancet Infectious Diseases·Evan W OrensteinAlison P Galvani
Apr 13, 2012·The European Respiratory Journal·Giovanni SotgiuGiovanni Battista Migliori
May 15, 2013·PloS One·Karen SheanKeertan Dheda
Nov 29, 2013·American Journal of Therapeutics·Shanshan WuSiyan Zhan
Apr 17, 2014·Annals of the American Thoracic Society·Karthickeyan DuraisamyAjay M V Kumar
Mar 18, 2015·PloS One·Yohanna Kamabi AvongPatrick Sunday Dakum
Mar 31, 2015·Lancet·Mukund UplekarUNKNOWN for WHO's Global TB Programme
Dec 18, 2015·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Basel KaroWalter Haas
Jan 4, 2017·International Journal of Mycobacteriology·Yi HuSven Hoffner
Mar 24, 2017·The European Respiratory Journal·Mayara Lisboa BastosDick Menzies
May 19, 2017·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Yang ZhangSiyan Zhan
Jul 12, 2017·Public Health Action·S L SuryawanshiM Parmar
Aug 23, 2017·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·H-Y YoonT S Shim
Oct 19, 2017·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A ReuterJ Furin
Nov 4, 2017·Lung India : Official Organ of Indian Chest Society·Arif I DelaKiran G Piparva
Nov 19, 2017·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A TrébucqH L Rieder
Mar 24, 2018·The European Respiratory Journal·Christine M HalleuxKarin Weyer
Mar 28, 2018·The Lancet Infectious Diseases·Simon TiberiAlimuddin Zumla
Aug 3, 2018·Seminars in Respiratory and Critical Care Medicine·Charles L Daley, Jose A Caminero
Sep 15, 2018·Lancet·UNKNOWN Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017Dick Menzies